Suppr超能文献

CXCL14 通过抑制 Akt/mTOR 通路抑制肝癌细胞的生长并促进其凋亡。

CXCL14 inhibits the growth and promotes apoptosis of hepatocellular carcinoma cells via suppressing Akt/mTOR pathway.

机构信息

Cangzhou Clinical Medical College of Integrated Traditional Chinese and Western Medicine, Hebei Medical University, Hebei, China.

Department of Emergency, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.

出版信息

J Recept Signal Transduct Res. 2021 Dec;41(6):593-603. doi: 10.1080/10799893.2020.1837870. Epub 2020 Oct 27.

Abstract

C-X-C motif chemokine ligand 14 (CXCL14) has antitumor effect. Kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway is activated in various tumors. The relationship between CXCL14 and Akt/mTOR pathway in hepatocellular carcinoma (HCC) remained elusive. Therefore, this paper aimed to examine their interaction in HCC. First, CXCL14 expression was determined to be low-expressed in HCC tissues and cells (SNU-423, SNU-182, SNU-387, PLC/PRF/5, HuH7, and HCCLM3). Then, CXCL14 was overexpressed in HuH7 cells and inhibited in HCCLM3 cells to help investigate the function of CXCL14 on cell viability, growth and apoptosis. Akt activator (SC79) and inhibitor (AZD5363) were used to examine the involvement of Akt pathway in hepatocellular carcinoma. Overexpressed CXCL14 suppressed cell viability and growth, but promoted the apoptosis by upregulated Bax and cleaved(C) caspase-3, donwregulated Bcl-2 and the inhibition of Akt and mTOR phosphorylation. Meanwhile, knockdown of CXCL14 imposed an opposite effect to overexpressed CXCL14. SC79 partially mitigated the functions of overexpressed CXCL14, while AZD5363 mitigated the functions of CXCL14 knockdown. To conclude, CXCL14 inhibited growth but promoted apoptosis of HCC cells via suppressing Akt/mTOR pathway, thus, CXCL14 might be a potential target for HCC treatment in clinical practice.

摘要

C-X-C 基序趋化因子配体 14(CXCL14)具有抗肿瘤作用。蛋白激酶 B(Akt)/哺乳动物雷帕霉素靶蛋白(mTOR)通路在各种肿瘤中被激活。然而,CXCL14 与肝癌(HCC)中的 Akt/mTOR 通路之间的关系仍不清楚。因此,本文旨在研究它们在 HCC 中的相互作用。首先,确定 CXCL14 在 HCC 组织和细胞(SNU-423、SNU-182、SNU-387、PLC/PRF/5、HuH7 和 HCCLM3)中表达水平较低。然后,在 HuH7 细胞中过表达 CXCL14,在 HCCLM3 细胞中抑制 CXCL14,以帮助研究 CXCL14 对细胞活力、生长和凋亡的功能。使用 Akt 激活剂(SC79)和抑制剂(AZD5363)来研究 Akt 通路在肝癌中的参与情况。过表达 CXCL14 抑制细胞活力和生长,但通过上调 Bax 和裂解(C)半胱天冬酶-3,下调 Bcl-2 以及抑制 Akt 和 mTOR 磷酸化来促进细胞凋亡。同时,敲低 CXCL14 对过表达 CXCL14 产生相反的效果。SC79 部分减轻了过表达 CXCL14 的功能,而 AZD5363 减轻了 CXCL14 敲低的功能。总之,CXCL14 通过抑制 Akt/mTOR 通路抑制 HCC 细胞的生长但促进其凋亡,因此,CXCL14 可能成为临床实践中 HCC 治疗的潜在靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验